EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Transforming growth factor-β2 is associated with atherosclerotic plaque stability and lower risk for cardiovascular events

Andreas Edsfeldt iD, Pratibha Singh, Frank Matthes iD, Christoffer Tengryd, Michele Cavalera, Eva Bengtsson, Pontus Dunér, Petr Volkov, Glykeria Karadimou, Anton Gisterå iD, Marju Orho-Melander iD, Jan Nilsson iD und 2 weitere

Cardiovascular Research · 05.09.2023 · 119 (11) · 2061-2073

DOI: 10.1093/cvr/cvad079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 18.05.2023. Verfasst von Andreas Edsfeldt und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden. Hauptthemen laut MEDLINE: Plaque, Atherosclerotic, Cardiovascular Diseases. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, Swedish Heart and Lung Foundation, Skåne University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Transforming growth factor-beta (TGF-β) exists in three isoforms TGF-β1, -β2, and -β3. TGF-β1 has been suggested to be important for maintaining plaque stability, yet the role of TGF-β2 and -β3 in atherosclerosis remains to be investigated. This study explores the association of the three isoforms of TGF-β with plaque stability in the human atherosclerotic disease. Methods and results TGF-β1, -β2, and -β3 proteins were quantified in 223 human carotid plaques by immunoassays. Indications for the endarterectomy were: symptomatic carotid plaque with stenosis >70% or without symptoms and >80% stenosis. Plaque mRNA levels were assessed by RNA sequencing. Plaque components and extracellular matrix were measured histologically and biochemically. Matrix metalloproteinases and monocyte chemoattractant protein-1 (MCP-1) was measured with immunoassays. The effect of TGF-β2 on inflammation and protease activity was investigated in vitro using THP-1 and RAW264.7 macrophages. Patients were followed longitudinally for cardiovascular (CV) events. TGF-β2 was the most abundant isoform and was increased at both protein and mRNA levels in asymptomatic plaques. TGF-β2 was the main determinant separating asymptomatic plaques in an Orthogonal Projections to Latent Structures Discriminant Analysis. TGF-β2 correlated positively to features of plaque stability and inversely to markers of plaque vulnerability. TGF-β2 was the only isoform inversely correlated to the matrix-degrading matrix metalloproteinase-9 and inflammation in the plaque tissue. In vitro, TGF-β2 pre-treatment reduced MCP-1 gene and protein levels as well as matrix metalloproteinase-9 gene levels and activity. Patients with plaques with high TGF-β2 levels had a lower risk to suffer from future CV events.

Conclusions

TGF-β2 is the most abundant TGF-β isoform in human plaques and may maintain plaque stability by decreasing inflammation and matrix degradation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plaque, AtheroscleroticCardiovascular DiseasesHumansTransforming Growth Factor beta2Transforming Growth Factor beta1Matrix Metalloproteinase 9Constriction, PathologicTransforming Growth Factor betaProtein IsoformsRNA, MessengerInflammationTransforming Growth Factors

Stichwörter der Autor:innen

AtherosclerosisExtracellular matrixInflammationPlaque stabilityTGF-β

Substanzen

Transforming Growth Factor beta2Transforming Growth Factor beta1Matrix Metalloproteinase 9Transforming Growth Factor betaProtein IsoformsRNA, MessengerTransforming Growth Factors

Autor:innen und Institutionen

  • Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden.
  • Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden.
  • Department of Cardiology, Skåne University Hospital, Malmö, Sweden.
  • Faculty of Health and Society, Malmö University, Malmö, Sweden.
  • Biofilms-Research Center for Biointerfaces, Malmö University, Malmö, Sweden.
  • Department of Clinical Sciences, LUDC Bioinformatics Unit, Malmö, Lund University, Lund, Sweden.

ORCID-Profile: Andreas Edsfeldt, Frank Matthes, Anton Gisterå, Marju Orho-Melander, Jan Nilsson, Isabel Gonçalves

Förderung

  • Swedish Research Council
  • Swedish Heart and Lung Foundation
  • Skåne University Hospital
  • Påhlsson Foundation
  • Crafoord Foundation
  • Swedish Society for Medical Research
  • Swedish Society of Medicine
  • Lund University Diabetes Centre

Zitieren

APA

Edsfeldt, A., Singh, P., Matthes, F., Tengryd, C., Cavalera, M., Bengtsson, E., Dunér, P., Volkov, P., Karadimou, G., Gisterå, A., Orho-Melander, M., Nilsson, J., Sun, J., & Gonçalves, I. (2023). Transforming growth factor-β2 is associated with atherosclerotic plaque stability and lower risk for cardiovascular events. Cardiovascular Research, 119(11), 2061-2073. https://doi.org/10.1093/cvr/cvad079

Vancouver

Edsfeldt A, Singh P, Matthes F, Tengryd C, Cavalera M, Bengtsson E, et al. Transforming growth factor-β2 is associated with atherosclerotic plaque stability and lower risk for cardiovascular events. Cardiovascular Research. 2023;119(11):2061-2073. doi:10.1093/cvr/cvad079

BibTeX
@article{Edsfeldt2023,
  author = {Edsfeldt, Andreas and Singh, Pratibha and Matthes, Frank and Tengryd, Christoffer and Cavalera, Michele and Bengtsson, Eva and Dunér, Pontus and Volkov, Petr and Karadimou, Glykeria and Gisterå, Anton and Orho-Melander, Marju and Nilsson, Jan and Sun, Jiangming and Gonçalves, Isabel},
  title = {Transforming growth factor-β2 is associated with atherosclerotic plaque stability and lower risk for cardiovascular events},
  journal = {Cardiovascular Research},
  year = {2023},
  volume = {119},
  number = {11},
  pages = {2061--2073},
  doi = {10.1093/cvr/cvad079}
}
Kostenlos starten →